Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization
Ind-Swift Laboratories Ltd · Others (Uncategorized) · 30 Oct 2026, 2:14 am
Ind-Swift Laboratories Reports Nil Deviation and Full Preferential Issue Proceeds Utilization Ind-Swift Laboratories confirmed zero deviation in utilizing proceeds from its 30th Aug'24 preferential issue of 2.60 crore convertible warrants. Total realizable proceeds were revised to ₹255.61 crore (against the original issue size of ₹314.60 crore) as ₹58.99 crore became non-receivable following an allottee's failure to exercise conversion rights by 28th Feb'26. The company has fully deployed the received ₹255.61 crore across business expansion (₹113.54 crore), general corporate purposes (₹75.00 crore), working capital (₹39.60 crore), and subsidiary investments (₹27.47 crore) as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. · 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. · 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 · 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants · 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants · 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... · 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 · 30 Oct 2026
- Please refer attached pdf · 30 Oct 2026
